Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 8Colorectal Neoplasms 7Lung Neoplasms 6Prostatic Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Fallopian Tube Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2

Interventions

Rituximab 17Cyclophosphamide 9fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Lenalidomide 6Filgrastim 6Mycophenolic Acid 5ibritumomab tiuxetan 4Whole-Body Irradiation 4Indium 4Everolimus 4Bortezomib 4romidepsin 3Sirolimus 3Etoposide 3Cyclosporine 3temsirolimus 2bazlitoran 2alvocidib 2Tacrolimus 2Radiotherapy 2Prednisone 2Methotrexate 2In Situ Hybridization, Fluorescence 2Ifosfamide 2Gene Expression Profiling 2Carboplatin 2Busulfan 2Biopsy 2Antilymphocyte Serum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Waldenstrom Macroglobulinemia × Specimen Handling × Clear all
NCT07420959 2026-02-19

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Mayo Clinic

Phase 1/2 Not yet recruiting
38 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡